|
|
|
|
|
|
|
04.09.25 - 05:42
|
Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock (Business Wire)
|
|
|
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced the pricing of its previously announced public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker has granted the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock. The offering is expected to close on or about September 8, 2025, subject to customary closing conditions.
Bruker estimates that the net proceeds from this offering will be approximately $582.0 million (or approximately $669.5 million if the underwriters exercise their option to purchase Mandatory Convertible Preferred Stock in full), in each case after deducting the underwriting discounts and commissions and estimated offering expenses payable by Bruker. Bruker intends to use the net proceeds from this offering to strengthen the balance sheet and enha...
|
|
|
|
|
|
|
|
|
|
|
02.09.25 - 22:03
|
Bruker Announces Public Offering of $600 Million of Mandatory Convertible Preferred Stock (Business Wire)
|
|
|
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker expects to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock, solely to cover over-allotments, if any.
Bruker intends to use the net proceeds from this offering to strengthen the balance sheet and enhance strategic flexibility by repaying (i) its term loan due December 2026 in full, (ii) outstanding borrowings under its 2024 amended and restated revolving credit agreement in full, and (iii) a portion of its term loan due March 2027. If the underwriters exercise their option to purchase additional Mandatory Convertible Preferred Stock, Bruker intends to use the net proceeds from the sale of such...
|
|
|
15.08.25 - 08:06
|
Polymer Factory Sweden (publ) Interim report Q2 2025 (Cision)
|
|
|
Second quarter, April-June 2025
· Earnings increased by 87% during the quarter compared to Q2 2024
· Polymer Factory announces a substantial order of SpheriCal® products
· The company signed a Supply Agreement with Global Leader in Scientific Instrumentation
· Polymer Factory Receives Order from International Energy Company
· Bruker launches QSee™ in partnership with Polymer Factory
Comments from CEO Mats Wallnér
During the second quarter of 2025, we saw improved financial balance in the company – revenues increased significantly while costs were reduced. This is a sign of...
|
|
|
|
|
12.08.25 - 13:06
|
Bruker Announces Quarterly Dividend (Business Wire)
|
|
|
BILLERICA, Mass.--(BUSINESS WIRE)--$BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis...
|
|
|
|
|
|
|
|
|
|
|
04.08.25 - 16:00
|
Bruker (BRKR) Misses Q2 Earnings Estimates (Zacks)
|
|
|
Bruker (BRKR) delivered earnings and revenue surprises of -3.03% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...
|
|
|
|
|
|
|
04.08.25 - 13:06
|
Bruker Reports Second Quarter 2025 Financial Results (Business Wire)
|
|
|
Q2 2025 revenues of $797.4 million, down 0.4% year-over-year (yoy); organic revenue down 7.0%, and constant-exchange rate (CER) revenue down 3.3%
Q2 2025 GAAP diluted EPS $0.05; non-GAAP diluted EPS $0.32
Announcing a significantly expanded cost savings initiative expected to reduce annual costs by $100 - $120 million in FY 2026
Recent additional key innovations for profitable growth acceleration in post-genomic disease biology research and next-gen drug discovery and development:
timsOmni: ushers in era of functional proteomics and proteoform analysis - at depth
timsMetabo: unprecedented annotation confidence in 4D metabolomics - with ultra-high sensitivity at speed and scale
timsUltra AIP: ultra-high sensitivity 4D single-cell proteomics and immunopeptidomics
Biocrates acquisition expands Bruker multiomics solutions with unique consumables, software and specialty CRO services for quantitative metabolomics
Updated FY2025 guidance:
Revenue $3.43 to $3.50 billion, with reported growth of 2% to 4% yoy, CER ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
